Vabysmo · DIN 02554003 · 6 mg/0.05 mL · injection, 0.05 mL pre-filled syringe (preservative-free)
Limited Use, Reason for Use code 649, 650, 725 requiredMarketed · checked November 18, 2026
StatusLimited Use, Reason for Use code 649, 650, 725 required
Write on scriptone applicable Reason for Use code, 649 or 650 or 725 (criteria below)
Patient paysIf the Reason for Use code is written and the criteria are met, ODB 65 and over pays:
• ODB senior: $100/program-year deductible
• Then up to $6.11 per prescription
• Or, if enrolled in the Seniors Co-Payment Program (income-tested; individual net income below $25,480 for Aug 2026–Jul 2027): no deductible, up to $2 per prescription
If the criteria are not met, ODB does not pay this product under Limited Use. [Limited Use benefit, Formulary flag]
Private plan not entered. Private-plan coverage, and how it coordinates with public programs, is not determined here; the Ontario public-program lines on this page remain conditional on the entered details and the program rules.
Ontario Limited Use criteria, code 649, 650, 725
Reason for Use code 649
For the treatment of patients with neovascular (wet) age-related macular degeneration (AMD) in a treatment-naive eye.
Initial diagnosis should be confirmed by an appropriate diagnostic procedure and administration should be done by a qualified ophthalmologist experienced in intravitreal injections.
Patients receiving concurrent administration of verteporfin PDT (Visudyne), ranibizumab (Lucentis), aflibercept (Eylea) or brolucizumab (Beovu) are not eligible for reimbursement.
Treatment should be initiated with an intravitreal injection every 4 weeks for the first 4 doses, followed by one injection every 8 to 16 weeks based upon disease activity.
Treatment with anti-VEGF agents should only be continued in patients who maintain adequate response to therapy.
For clarity, coverage will be provided for patients responding to therapy with another anti-VEGF agent who switch to Vabysmo. Coverage will NOT be provided for patients who have failed to respond to other anti-VEGF agents.
Coverage limit:
LU Authorization Period: 1 year
Reason for Use code 650
For the treatment of patients with clinically significant diabetic macular edema (DME) for whom laser photocoagulation is also indicated; and who have a hemoglobin A1c of less than 12 percent.
Vabysmo is to be administered using one of the following dosing regimens:
Treatment should be initiated with an intravitreal injection every 4 weeks for the first 6 doses, followed by an intravitreal injection at a dosing interval of every 8 weeks.
OR
Treatment should be initiated with an intravitreal injection every 4 weeks for the first 4 doses or until macular edema is resolved. Thereafter, the dosing interval may be extended up to every 16 weeks (4 months) in up to 4-week increments. If anatomic and/or visual outcomes deteriorate, then the treatment interval should be shortened accordingly.
Treatment with anti-VEGF agents should only be continued in patients who maintain adequate response to therapy.
For clarity, coverage will be provided for patients responding to therapy with another anti-VEGF agent who switch to Vabysmo. Coverage will NOT be provided for patients who have failed to respond to other anti-VEGF agents.
Coverage limit:
LU Authorization Period: 1 year
Reason for Use code 725
For the treatment of patients with clinically significant macular edema secondary to branch retinal vein occlusion (BRVO) or central retinal vein occlusion (CRVO).
Treatment should be initiated with an intravitreal injection every 4 weeks until stable visual acuity improvement and disease control are achieved.
The treatment interval may be extended up to 16 weeks (4 months) in up to 4-week increments at a time in patients without disease activity.
If anatomic and/or visual outcomes deteriorate, the treatment interval should be shortened accordingly. The interval between doses should not be shorter than one month.
Patients should be assessed regularly. Treatment with anti-VEGF agents should only be continued in patients who maintain adequate response to therapy.
For clarity, coverage will be provided for patients responding to therapy with another anti-VEGF agent who switch to this product. Coverage will NOT be provided for patients who have failed to respond to other anti-VEGF agents.
Coverage limit:
LU Authorization Period: 1 year
No interchangeable product listed in the Ontario extract
Vabysmo · DIN 02554003
Manufacturer: Hoffmann-La Roche Limited; listing date 2025-10-31
Health Canada: Marketed since 2025-06-30 · brand VABYSMO · ATC S01LA09 FARICIMAB · form Solution · route Intravitreal · ingredients FARICIMAB 6 MG/0.05ML · company Hoffmann-la roche limited · schedule Schedule d, Prescription
Vabysmo: Formulary list price $1350.00 per unit (the source does not state the unit; exact figure $1350.0000). What the ministry pays, not the patient.
Formulary data: Ontario extract of September 22, 2026 · Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · Health Canada DPD page · Verify on the e-Formulary ↗ (DIN 02554003)
Source record
DIN 02554003: Vabysmo
Raw flags: sec12=Y, sec3=Y
Item: 523600159; group id 625; item number 1593; lccId 00371; manufacturer id HLR
Source form: Inj Sol-0.05mL Pref Syr (Preservative-Free); strength: 6mg/0.05mL
Recorded listing: Limited Use: paid only with a Reason for Use code and the criteria below
Source prices (unrounded): $1350.0000; ministry $1350.0000
Source: ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=September 22, 2026 DIN=02554003
Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=104289
Shortage status: not checked (no credentials)